Irish HSE to review reimbursement status for Friedreich's ataxia drug Skyclarys

The Irish Health Service Executive (HSE) is convening to determine the funding and availability of Skyclarys for patients with Friedreich's ataxia. The outcome remains uncertain, as the decision hinges on cost-effectiveness assessments and budgetary constraints for rare disease treatments.